<?xml version="1.0" encoding="UTF-8"?>
<p content-type="disclosure">I. Alfradique-Dunham, R. Al-Ouran, R. von Coelln, C. Blauwendraat, E. Hill, L. Luo, A. Stillwell, E. Young, A. Kaw, M. Tan, C. Liao, L. Pihlstrom, J. Marinus, J.J. Van Hilten, D. Grosset, L. Shulman, Z. Liu, G. Rouleau, M. Nalls, A. Singleton, and J. Jankovic report no disclosures relevant to the manuscript. Dr. Nalls consults for Illumina Inc, Lysosomal Therapeutics Inc, the Michael J. Fox Foundation, and Vivid Genomics among others. H Morris is employed by UCL and discloses paid consultancy from Biogen, UCB, AbbVie, Denali, Biohaven, and Lundbeck and lecture fees/honoraria from Biogen, UCB, C4X Discovery, GE Healthcare, Wellcome Trust, and the Movement Disorders Society. Dr Morris is a coapplicant on a patent application related to C9ORF72â€”Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). Dr. Grossett received honoraria from GE Healthcare, Bial Pharma, and Vectura plc and consultancy fees from The Glasgow Memory Clinic. J. Shulman consults for the Adrienne Helis Malvin &amp; Diana Helis Henry Medical Research Foundations. Full disclosure form information provided by the authors is available with the full text of this article at 
 <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000557" xmlns:xlink="http://www.w3.org/1999/xlink">Neurology.org/NG</ext-link>.
</p>
